Risultati per: Scompenso Cardiaco. Gestione in MG dalla diagnosi al follow-up

In Italia 5 mln di pazienti. Gemmato, ‘migliori cure e risparmi’. Locatelli, ‘curare la persona e non solo la malattia’

In Italia 5 mln di pazienti. Gemmato,

Fondazione Telethon tra le organizzazioni

Circulation, Volume 149, Issue 11, Page 896-896, March 12, 2024.

Circulation, Volume 149, Issue 11, Page 892-893, March 12, 2024.

Circulation, Volume 149, Issue 11, Page 894-895, March 12, 2024.

Solo l’1% delle ricerche sono dedicate a condizioni specifiche di genere. Intervista alla neuroscienziata Antonella Santuccione Chadha: «Donne enorme bacino di pazienti sottodiagnosticato»

E’ una condizione genetica ereditaria che aumenta il rischio di malattia oncologica

Sesti (Simi), ‘intercetta precocemente i soggetti a rischio. Cure più tempestive’

Stroke, Ahead of Print. Background:Stroke with unknown time of onset can be categorized into 2 groups; wake-up stroke (WUS) and unwitnessed stroke with an onset time unavailable for reasons other than wake-up (non–wake-up unwitnessed stroke, non-WUS). We aimed to assess potential differences in the efficacy and safety of intravenous thrombolysis (IVT) between these subgroups.Methods:Patients with an unknown-onset stroke were evaluated using individual patient-level data of 2 randomized controlled trials (WAKE-UP [Efficacy and Safety of MRI-Based Thrombolysis in Wake-Up Stroke], THAWS [Thrombolysis for Acute Wake-Up and Unclear-Onset Strokes With Alteplase at 0.6 mg/kg]) comparing IVT with placebo or standard treatment from the EOS (Evaluation of Unknown-Onset Stroke Thrombolysis trial) data set. A favorable outcome was prespecified as a modified Rankin Scale score of 0 to 1 at 90 days. Safety outcomes included symptomatic intracranial hemorrhage at 22 to 36 hours and 90-day mortality. The IVT effect was compared between the treatment groups in the WUS and non-WUS with multivariable logistic regression analysis.Results:Six hundred thirty-four patients from 2 trials were analyzed; 542 had WUS (191 women, 272 receiving alteplase), and 92 had non-WUS (42 women, 43 receiving alteplase). Overall, no significant interaction was noted between the mode of onset and treatment effect (Pvalue for interaction=0.796). In patients with WUS, the frequencies of favorable outcomes were 54.8% and 45.5% in the IVT and control groups, respectively (adjusted odds ratio, 1.47 [95% CI, 1.01–2.16]). Death occurred in 4.0% and 1.9%, respectively (P=0.162), and symptomatic intracranial hemorrhage in 1.8% and 0.3%, respectively (P=0.194). In patients with non-WUS, no significant difference was observed in favorable outcomes relative to the control (37.2% versus 29.2%; adjusted odds ratio, 1.76 [0.58–5.37]). One death and one symptomatic intracranial hemorrhage were reported in the IVT group, but none in the control.Conclusions:There was no difference in the effect of IVT between patients with WUS and non-WUS. IVT showed a significant benefit in patients with WUS, while there was insufficient statistical power to detect a substantial benefit in the non-WUS subgroup.REGISTRATION:URL:https://www.clinicaltrials.gov; Unique identifier: CRD42020166903.

Stroke, Ahead of Print.

Settimana mondiale. Iapb, liste attesa per visite troppo lunghe

Objective
As achalasia is a chronic disorder, long-term follow-up data comparing different treatments are essential to select optimal clinical management. Here, we report on the 10-year follow-up of the European Achalasia Trial comparing endoscopic pneumodilation (PD) with laparoscopic Heller myotomy (LHM).

Design
A total of 201 newly diagnosed patients with achalasia were randomised to either a series of PDs (n=96) or LHM (n=105). Patients completed symptom (Eckardt score) and quality-of-life questionnaires, underwent functional tests and upper endoscopy. Primary outcome was therapeutic success defined as Eckardt score